Last reviewed · How we verify
Intravitreous injection of ranibizumab
Intravitreous injection of ranibizumab is a Small molecule drug developed by José Cunha-Vaz. It is currently in Phase 2 development.
At a glance
| Generic name | Intravitreous injection of ranibizumab |
|---|---|
| Sponsor | José Cunha-Vaz |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema (PHASE3)
- A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) (PHASE2)
- ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration (PHASE1)
- A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy (PHASE3)
- A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy (PHASE3)
- A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration (PHASE2)
- A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration (PHASE1)
- Ranibizumab and Bevacizumab for Diabetic Macular Edema (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravitreous injection of ranibizumab CI brief — competitive landscape report
- Intravitreous injection of ranibizumab updates RSS · CI watch RSS
- José Cunha-Vaz portfolio CI
Frequently asked questions about Intravitreous injection of ranibizumab
What is Intravitreous injection of ranibizumab?
Intravitreous injection of ranibizumab is a Small molecule drug developed by José Cunha-Vaz.
Who makes Intravitreous injection of ranibizumab?
Intravitreous injection of ranibizumab is developed by José Cunha-Vaz (see full José Cunha-Vaz pipeline at /company/jos-cunha-vaz).
What development phase is Intravitreous injection of ranibizumab in?
Intravitreous injection of ranibizumab is in Phase 2.